TY - JOUR
T1 - Radiation treatment for adult rare cancers
T2 - Oldest and newest indication
AU - Fiorentino, Alba
AU - Gregucci, Fabiana
AU - Desideri, Isacco
AU - Fiore, Michele
AU - Marino, Lorenza
AU - Errico, Angelo
AU - Di Rito, Alessia
AU - Borghetti, Paolo
AU - Franco, Pierfrancesco
AU - Greto, Daniela
AU - Donato, Vittorio
N1 - Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/3
Y1 - 2021/3
N2 - Aim: Aim of this analysis is to review the role of RT in the management of several rare tumors for adult patients. Methods: Collection data regarding RT and rare tumors was made by Pubmed. Results: For mucosal melanomas, RT is prescribed, being associated with lower local recurrence rate. For trachea tumors, RT was used as adjuvant or salvage treatment for unresectable disease. For pNET, RT can be a suitable option for post-surgical or unresectable/borderline. For bronchopulmonary neuroendocrine tumors the role of adjuvant treatments is uncertain. For hepatobiliary and ovarian malignancy, stereotactic body RT (SBRT) is a promising approach. For soft tissue sarcoma, perioperative treatments are indicated, and a growing role of SBRT in oligometastatic disease is recognized. For endocrine tumors, adjuvant RT has demonstrated benefits through reducing recurrence risk. Conclusion: The radiotherapy is a frequent indication in adult rare cancers; thus the role of Radiation Oncologist must not be neglected.
AB - Aim: Aim of this analysis is to review the role of RT in the management of several rare tumors for adult patients. Methods: Collection data regarding RT and rare tumors was made by Pubmed. Results: For mucosal melanomas, RT is prescribed, being associated with lower local recurrence rate. For trachea tumors, RT was used as adjuvant or salvage treatment for unresectable disease. For pNET, RT can be a suitable option for post-surgical or unresectable/borderline. For bronchopulmonary neuroendocrine tumors the role of adjuvant treatments is uncertain. For hepatobiliary and ovarian malignancy, stereotactic body RT (SBRT) is a promising approach. For soft tissue sarcoma, perioperative treatments are indicated, and a growing role of SBRT in oligometastatic disease is recognized. For endocrine tumors, adjuvant RT has demonstrated benefits through reducing recurrence risk. Conclusion: The radiotherapy is a frequent indication in adult rare cancers; thus the role of Radiation Oncologist must not be neglected.
KW - Adult rare cancer
KW - Radiotherapy
KW - SBRT
KW - Stereotactic radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85099960325&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2021.103228
DO - 10.1016/j.critrevonc.2021.103228
M3 - Review article
SN - 1040-8428
VL - 159
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
M1 - 103228
ER -
